Literature DB >> 11241132

The C-terminal domain of thrombospondin-1 induces vascular smooth muscle cell chemotaxis.

S M Nesselroth1, A I Willis, S Fuse, E T Olson, J Lawler, B E Sumpio, V Gahtan.   

Abstract

OBJECTIVE: Thrombospondin-1 (TSP-1), an acute-phase reactant implicated in vascular disease, is a 420-kd multifunctional glycoprotein chemotactic for vascular smooth muscle cells (VSMCs). TSP-1 has six domains of repeating homologous amino acid sequences: N-terminal, procollagen homology, type 1 repeat, type 2 repeat, type 3 repeat/RGD (T3), and C-terminal (COOH). The purpose of this experiment was to determine which domains of TSP-1 induce VSMC chemotaxis.
METHODS: A modified Boyden Chamber chemotaxis assay was used to assess VSMC migration. Serum-free medium, TSP-1, or each of the fusion proteins (10 and 20 microg/mL) synthesized for the different domains were placed in the bottom wells. Quiescent bovine aortic VSMCs (50,000) were placed in the top wells. After 4 hours at 37 degrees C, migrated VSMCs were recorded as cells per five fields (400x) and analyzed with the paired t test. To verify the fusion protein data, we performed chemotaxis assays with antibodies to each of the domains (25 microg/mL) combined with TSP-1 (20 microg/mL) in the bottom wells and VSMCs in the top wells.
RESULTS: The COOH domain significantly stimulated VSMC chemotaxis (P = <.001). To a lesser extent, the N-terminal and T3 domains also induced chemotaxis (P <.05). However, only the anti-COOH antibody (C6.7) and the anti-integrin-associated protein portion of COOH antibody (D4.6) significantly inhibited TSP-1-induced VSMC chemotaxis (by 85% and 92%, respectively).
CONCLUSIONS: These results implicate the COOH domain as the portion of the TSP-1 molecule primarily responsible for VSMC chemotaxis. This experiment suggests that future strategies in the prevention of VSMC migration, an initial step in the development of vascular lesions, may involve selective inhibition of the COOH domain of TSP-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241132     DOI: 10.1067/mva.2001.112318

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.

Authors:  Mingyi Yao; David D Roberts; Jeff S Isenberg
Journal:  Pharmacol Res       Date:  2010-10-29       Impact factor: 7.658

2.  Thrombospondin-1 differentially regulates microRNAs in vascular smooth muscle cells.

Authors:  Kristopher G Maier; Brian Ruhle; Jeffrey J Stein; Karen L Gentile; Frank A Middleton; Vivian Gahtan
Journal:  Mol Cell Biochem       Date:  2016-01-04       Impact factor: 3.396

3.  Function-blocking antithrombospondin-1 monoclonal antibodies.

Authors:  D S Annis; J E Murphy-Ullrich; D F Mosher
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

4.  Cyclic stretch affects pulmonary endothelial cell control of pulmonary smooth muscle cell growth.

Authors:  Cristhiaan D Ochoa; Haven Baker; Stephen Hasak; Robina Matyal; Aleya Salam; Charles A Hales; William Hancock; Deborah A Quinn
Journal:  Am J Respir Cell Mol Biol       Date:  2008-02-28       Impact factor: 6.914

5.  Activin B signaling may promote the conversion of normal fibroblasts to scar fibroblasts.

Authors:  Shi-Kang Deng; Jian-Zhong Tang; Yan Jin; Ping-Hai Hu; Jun-Feng Wang; Xiao-Wen Zhang
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.